ArticleCureus2025
A Case of Coexistence of Esophageal Squamous Cell Carcinoma and Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IL-11-IL6ST-STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal malignancy is a prevalent cancer both in the United States and globally. In the United States, adenocarcinoma is a particularly common esophageal malignancy, likely secondary to gastroesophageal reflux disease (GERD) and Barrett's esophagus. Conversely, squamous cell carcinoma (SCC) is the most common histology globally, especially prevalent in Asian countries, in what is known as the esophageal cancer belt. SCC and adenocarcinoma of the esophagus have clinical, oncologic, and histologic differences suggesting the need for tailored therapeutic approaches. In some cases, patients with concurrent risk factors for both malignancies can present with a collision tumor or adjacent tumors with two histologic subtypes within a single mass, and this warrants a unique treatment strategy. A case such as this one, involving a patient presenting with simultaneous poorly differentiated SCC as well as high-grade adenocarcinoma in the background of tubulovillous adenoma-like change, presents a unique clinical course and a possible example of a collision tumor. Furthermore, the differing prognostic indicators for both squamous and adenocarcinoma of the esophagus can highlight the importance of individualized treatment plans to improve both patient satisfaction and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.